Founded Year
2018Stage
Series A - III | AliveTotal Raised
$59.08MLast Raised
$35M | 1 yr agoExpert Collections containing Lupeng Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Lupeng Pharma is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Latest Lupeng Pharma News
Jul 30, 2021
publication date: Jul 30, 2021 Guangzhou Lupeng Pharmaceutical completed a $35 million pre-B financing led by Temasek. The company will use the funds for global clinical development of its lead drug, a selective Bcl-2 inhibitor, along with advancing at least four other candidates into clinical trials. Founded in 2018, Lupeng aims to develop global best-in-class therapies. The company develops novel small molecule drugs for cancer, hepatitis B and autoimmune diseases. Lupeng is approved to conduct clinical trials of its lead Bcl-2 inhibitor in China
When was Lupeng Pharma founded?
Lupeng Pharma was founded in 2018.
Where is Lupeng Pharma's headquarters?
Lupeng Pharma's headquarters is located at Guangzhou.
What is Lupeng Pharma's latest funding round?
Lupeng Pharma's latest funding round is Series A - III.
How much did Lupeng Pharma raise?
Lupeng Pharma raised a total of $59.08M.
Who are the investors of Lupeng Pharma?
Investors of Lupeng Pharma include Lilly Asia Ventures, FC Capital, Temasek, Lake Bleu Capital, Kaitai Capital and 4 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.